English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Lonza Group AG
Suletud
536 0.49
Ülevaade
Aktsiahinna muutus
24h
Min
536
Max
539.4
Sissetulek | 244M |
|---|---|
Müük | -582M 3.1B |
P/E Sektori keskmine | 26.67 |
Aktsiakasum | 4.61 |
Kasumimarginaal | 6.705 |
Turukapital | -144M 40B |
|---|---|
Eelmine avamishind | 535.51 |
Eelmine sulgemishind | 536 |
Uudiste sentiment
By Acuity
50%
50%
Lonza Group AG Graafik
Seotud uudised
Lonza Group AG Prognoos
Sentiment
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Lonza Group AG
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.